Dr Horowitz: Dr Robertson & Novavax Responsible For Strain of "Swine" Flu

[phreekshow]

http://www.youtube.com/watch?v=GBeKB7aKzOs

[America2]

http://news.bbc.co.uk/2/hi/americas/8022958.stm

Ms Vassiliou said the EU would from now on refer to the outbreak as "novel flu" to avoid any misleading link with pigs or the pork industry.

She said that was a "wrong connotation". Experts say there has been no sign of any direct link with pigs.

[squarepusher]

Boyboy - the bureaucrats get in on the whole horse-and-buggy show - now we're going to create a lot of fuss about the 'name', and which 'institution' or 'industry' could be 'offended'.

[db]

The novel must be 1984.

Frigging PC Europeans!

[EvadingGrid]

The novel must be 1984.

Frigging PC Europeans!

Bugger off ob, call it "American Flu"

Its  probably got made in the usa tattooed on its arse if you had a powerfull enough microscope

[Xill]

Gosh they are going out of their mind with this flu. More people are dying from car accidents every minutes. I've never seen something pushed as much as this this in the media and governement.

I PREDICT this whole thing will turn against them like never before if the keep fear mongering.
Which makes me think: discrediting the medias is also part of the whole NWO take over of the medias.

[db]

Bugger off ob, call it "American Flu"

Its  probably got made in the usa tattooed on its arse if you had a powerfull enough microscope

Oh, I think we had some help from some European (and perhaps, Chinese) friends.

[Xill]

Novels!  Burn the books!  Don't touch them.  They're EVIL.
No telling what viruses are lurking in those old rotting pages.
OMG!  Where all going to DIE!

They dont need to burn the books anymore, Americans don't read books... And they don't have maps either! (according to South Carolina). http://www.youtube.com/watch?v=sAJUMYGgfZA

[EvadingGrid]

Oh, I think we had some help from some European (and perhaps, Chinese) friends.

Prob right

[db]

I've noticed that classic novels have been disapearing from the local library shelves
over the past 10 years.  The lost and damaged books are not being replaced.
At most you might find two maybe three ratty novels from a prolific author of the
past. Shameful.

In Brave New World people had to be conditioned to hate books and flowers.  Now children don't read anyway.

Truth is the people never read much anyway and when they read, they read mainly crap.

[Devotional Soul]

I don't know about these book things you're talking about, but I'm offended that they would name it Novel...that's America's #1 couple's daughter's middle name!  

JK, Now that I think of it, Angelina's CFR, she probably wanted it named after her kid...Shiloh Novel...the 'new messiah'.

[bushido_aria]

I've noticed that classic novels have been disapearing from the local library shelves
over the past 10 years.  The lost and damaged books are not being replaced.
At most you might find two maybe three ratty novels from a prolific author of the
past. Shameful.

I've been finding absolute gems of used books online from libraries that got rid of them. It made me rather angry when I would find 5 or 6 copies from various libraries online for sale. Was there a secret memo to purge these books? I don't have serious $$ to spend, but I always feel good when I find one. More of the human lexicon saved. And I agree with you, it is a travesty and utterly shameful.

BTW, the books I was hunting down were all about the Holocaust and martial law in Germany. Coincidence? I think not.

[db]

Okay, Brangelina Flu.

Says it all.

[Xill]

Huh, no one picked up on this yet, Novel can also mean new; like in french: "Nouvel" or "Nouvelle" (meaning both "new" and "short story")

Edit; exactly: http://en.wikipedia.org/wiki/Novel


I would be surprise at all if the Illuminati used the old meaning of the word, therefore we have something more in the line of the "New Flu"

[db]

Um, yeah.  I got that.

Actually, novels are "romans" -- "en Francais."

[Kandyk438]

Huh, no one picked up on this yet, Novel can also mean new; like in french: "Nouvel" or "Nouvelle" (meaning both "new" and "short story")

Edit; exactly: http://en.wikipedia.org/wiki/Novel


I would be surprise at all if the Illuminati used the old meaning of the word, therefore we have something more in the line of the "New Flu"

Earlier today, I was reading a flu article and saw "non-typical" flu's referred to as "novel" so that meaning clicked right away for me. 

[Sane]

This is the "welcome flu" as in...



"Welcome to the New World Order sheep-biyatches!"

[EvadingGrid]

This is the "welcome flu" as in...



"Welcome to the New World Order sheep-biyatches!"

ROFL

[Devotional Soul]

oh no, it's the sheep flu, too? 

[db]

Welcome to the New World Order, where men are men and sheep are scared!

[EvadingGrid]

Welcome to the New World Order,
where men are men
and sheeple are scared!

Some one oughta stick that on a T-shirt

[Devotional Soul]

Dr. Leo knows what he's talking about.  Thanks for the video.

When I first started researching vaccines, I learned my state didn't have exemption from the tb test.  He was in the same state and refused to let his straight A high school daughter get the tb test and went to court and won the case, and tried to pass bills to change the laws.  I've chatted with him and he has been trying to spread the silver for a long time now.

[Alchematron]

Explosive!

Alex needs Len back on the show pronto!

[KiwiClare]

I bet the chosen name is Novel because the vaccine company that is geared up to provide the "solution" is NOVOVAX. 

MUST SEE: Watch this 10 mins presentation by Dr Len Horowitz. http://www.youtube.com/watch?v=GBeKB7aKzOs

Refer:
Novavax sees world of vaccine plants
http://www.gazette.net/stories/032808/businew202056_32374.shtml
Rockville biotech set to open demonstration site of facility for global network

[db]

Some one oughta stick that on a T-shirt

Just cut me in for a few percent, please.

[jadem]

Novel Flu? European Commission said "North American Influenza" was more fitting 

[RickDaniels]

they were going to name it the "Amerixican flu"  but that name has been trademarked by the North American Union

[KiwiClare]

Dr Len Horowitz states in this 10.41 mins YouTube clip that the swine-bird-human flu strain in Mexico could have only come from Dr James S Robertson and colleagues because: "nobody else takes H5N1 Asian-flu infected chickens, brings them to Europe, extracts their DNA, combines their proteins with H1N1 viruses from the 1918 Spanish flu isolate, additionally mixes in some swine flu genes from pigs, then reverse engineers them to infect humans."

LISTEN http://www.youtube.com/watch?v=GBeKB7aKzOs


Also, Dr Horowitz indicates there is hard evidence to show that Dr James Robertson believe it is OK to prime populations worldwide by releasing viruses he and his colleagues are creating in advance of a pandemic. 

Dr Horowitz mentions Dr Rick Bright is involved.  Dr Bright has ties to the WHO, the CDC and Novovax Inc, and is involved in PATH - Influenza Vaccine Project in the Vaccine Development Global Program.

March 1st, 2006
Pharma product development company appoints Rick A. Bright as VP vaccine research

Novavax, Inc. (NVAX) announced the appointment of Rick A. Bright, PhD to the newly created position of vice president, vaccine research.

Bright will report directly to Dr. Rahul Singhvi, president and CEO of Novavax.

Bright joins Novavax following more than 15 years' experience as a researcher and expert on influenza vaccine and antiviral research, one of a handful of such experts in the world. Most recently he has served at the U.S. Centers for Disease Control (CDC) and Prevention in Atlanta, Georgia.

Bright worked in the Influenza Branch, Strain Surveillance Section, as immunologist and virologist, team leader of...

Source: Vaccine Weekly (2006-03-01)
http://www.newsrx.com/newsletters/Vaccine-Weekly/2006-03-01/03012006333119VW.html


Scientific Director, Influenza Vaccine Project in the Vaccine Development Global Program, PATH   Rick Bright
https://www.isirv.org/about/board-members/Rick-Bright/
Country of Residence: United States
Contact Information
PATH
1800 K Street, Suite 800
Washington, DC 20006
Phone: +1 202 822 0033
Fax: +1 202 457 1466
rbright@path.org

 
Mission

isirv will work for the prevention, detection, treatment, and control of influenza and other respiratory viral diseases throughout the world.

It will do so through the exchange and dissemination of information, through facilitating the interaction of scientists and public health specialists, and by promoting international collaborative efforts against these diseases.

Topics of interest to the organization include:

    * Diagnostics, epidemiology, and surveillance
    * Influenza and pandemic preparedness
    * Other respiratory viruses such as SARS and other coronaviruses, RSV, parainfluenza viruses, pneumoviruses, etc.
    * Vaccine development and evaluation
    * Antiviral research and evaluation
    * Clinical research and patient care
    * Cost benefit and health economics
    * Policy for control and prevention
    * Virus ecology, zoonoses, and animal viruses


The CDC has mentioned recently that they want to rename the virus from swine to Novel. It looks like that is because the vaccine manufacturer is NOVOVAX Inc.

[Sane]

NOVAVAX Announces Publication of
a Preclinical Study Demonstrating that
a Virus-like Particle Vaccine Provided Protection
Against Highly Pathogenic
H1N1 and H5N1 Influenza Strains
http://findarticles.com/p/articles/mi_m4PRN/is_2009_April_14/ai_n31529950/

April 14, 2009

H1N1 Virus-like Particle (VLP) Vaccine Candidate Based on the 1918 Spanish Influenza Strain Protected Mice and Ferrets Against the Spanish Flu and Highly Pathogenic H5N1 Bird Flu

ROCKVILLE, Md., April 14 /PRNewswire-FirstCall/ -- Novavax, Inc. today reported preclinical study results showing that an investigational H1N1 virus-like particle (VLP) vaccine based on the 1918 Spanish influenza strain protected against both the Spanish flu and a highly pathogenic H5N1 avian influenza strain. The study, published in the March 25, 2009 online issue of the Journal of Virology, was conducted by scientists from the Centers for Disease Control and Prevention (CDC) in Atlanta, GA and Novavax under a Collaborative Research and Development Agreement.

Novavax scientists designed and produced a recombinant VLP vaccine candidate against the 1918 H1N1 influenza strain. This 1918 influenza strain was responsible for more than 50 million deaths worldwide during the great Spanish flu pandemic. Mice and ferrets were vaccinated with VLPs by one of two routes: either by standard intramuscular injection or by administering a small drop of the VLP vaccine in the nose (intranasal immunization). All of the 1918 VLP-immunized animals were protected when exposed to a lethal dose of the 1918 influenza virus, regardless of the route by which the vaccine was administered. Remarkably, animals immunized by the intranasal route were also protected against a lethal dose of a contemporary, highly pathogenic avian influenza subtype H5N1 virus strain, isolated from a fatal human case in 2004 (A/Vietnam/1203/2004 strain).

The H1N1 VLP vaccine candidate was made up of the hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) proteins from 1918 Spanish influenza virus strains. These proteins, which were produced in insect cells, formed three-dimensional structures that mimic the 1918 pandemic influenza virus but without the genetic material needed for replication. The mechanism of action by which this H1N1 VLP vaccine candidate provided broad cross-protection is under further study, but the scientists described preliminary evidence that antibody cross-reactivity between the HA and possibly NA proteins of the H1N1 and H5N1 influenza were important.

"Unlike other non-live influenza vaccines, the VLPs are uniquely positioned to stimulate immunity through multiple mechanisms," said Dr. Penny Heaton, Chief Medical Officer at Novavax. "First, they contain HA protein that is the same structure as the live virus, which may stimulate HA antibodies of several types that not only prevent the virus from attaching to cells but also prevent the virus from fusing with cells. Second, the VLPs contain NA which may stimulate production of antibody that prevents spread of the virus down the respiratory tract. Finally, the structure of the HA and NA proteins and the way in which they are embedded in lipids on the surface of the VLP may activate the innate immune system providing protection against both the H1N1 and H5N1 strains," said Dr. Heaton.

Although cross protection against influenza strains of the same hemagglutinin or HA type has been achieved through the use of vaccines with adjuvants (e.g., cross-protection against H5N1 A/Vietnam and A/Indonesia strains), protection against strains with different HA types, as shown in this study, has not been reported. Cross-protection against different HA types is highly desirable for pandemic influenza vaccine candidates because it is not possible to predict the strain that may be responsible for the next pandemic with today's technology. A broadly cross-protective vaccine would be ideal for stockpiling in that it could be administered during the first wave of the pandemic while waiting for manufacture of vaccine specific to the pandemic strain.

Dr. Gale Smith, Vice President of Vaccine Development at Novavax, said, "The discovery that a VLP-based influenza vaccine candidate created through cell-based recombinant technology has the potential to protect against diverse strains of influenza has significant implications for both pre-pandemic and pandemic preparedness. A broadly protective vaccine administered prior to and during the first wave of a pandemic could prevent widespread morbidity and mortality from a newly emerged pandemic influenza strain and allow time for the development of strain-specific vaccines."

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary VLP technology. The company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. The Company has VLP vaccine candidates against seasonal influenza and potential pandemic influenza strains in phase II clinical development.

This report describes the second of two preclinical studies of Novavax's investigational H5N1 pandemic influenza vaccine announced this year that have shown different approaches to achieving broad protection against diverse influenza strains. As announced in February, a VLP vaccine with an HA based on several H5 strains showed broad cross-protection against different H5 strains. In the current study, an alternative route of administration resulted in cross-protection against different HA types. Novavax has shown in clinical trials that an H5N1 VLP candidate vaccine given by intramuscular injection is well tolerated and immunogenic in humans. Preclinical research on alternative pandemic influenza VLP vaccine approaches is expected to continue.

[Sane]

Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009
http://www.bio-medicine.org/biology-technology-1/Cleveland-Clinic-Recognizes-New-Strategies-for-Creating-Vaccines-for-Avian-Flu-as-a-Top-Ten-Medical-Innovation-for-2009-9194-1/
Date:11/13/2008

Novavax uses strategies to create vaccines for avian flu through genetically-engineered virus-like particles (VLPs)

ROCKVILLE, Md., Nov. 13 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that its strategy for treating avian flu through genetically-engineered virus-like particles (VLPs) was ranked as a Top Ten Innovation at Cleveland Clinic 6th Annual Medical Innovation Summit.

Novavax, Inc. believes its vaccine initiatives have the potential to impact millions of people affected by infectious diseases each year by creating novel vaccines that can be produced in a cost effective and timely manner within the same scalable manufacturing platform worldwide.

VLPs are recombinant structures that mimic the size and shape of a virus but lack genetic material and are therefore incapable of replication. Because they resemble actual infectious particles presenting proteins in the same conformation as on the wild-type virus, they are able to induce potent immune responses. Novavax's VLP vaccine may be differentiated from other influenza vaccines in several ways. First, it includes three viral proteins (incorporated in the vaccine as three separate VLPs) important for inducing a broad immune response including two surface proteins, hemmaglutinin ("HA") and neuraminidase ("NA"), and a core matrix protein, M1. The HA protein induces antibody that neutralizes or blocks the growth of the virus; NA induces antibodies that prevent cell-to-cell transmission of virus down the respiratory tract, potentially reducing the severity of influenza disease; and cell mediated immune responses to M1 may lead to destruction of cells already infected. Further, the vaccine is made in cell culture rather than eggs, which permits an exact genetic match to the flu strains causing illness since there is no requirement for adapting the vaccine to grow in eggs.

"We are proud to have our technology recognized by the Cleveland Clinic as one of the top ten medical innovations of 2009," said Dr. Rahul Singhvi, President and CEO of Novavax. "VLPs represent a very promising approach to preventing the spread of influenza as we recently demonstrated with the announcement of favorable results in a Phase IIa human clinical trial of our VLP based pandemic influenza vaccine.

Novavax's Novel Manufacturing Approach

Novavax's manufacturing process makes it possible to potentially produce and distribute a vaccine matched to a pandemic strain in time to interrupt and/or halt a pandemic. Novavax's influenza VLPs are produced in insect cell culture, utilizing a manufacturing process that consists entirely of disposable, ready-to-use equipment. Current yields are 7 to 10 times higher than that of traditional egg-based or mammalian cell culture manufacturing. Because the Novavax process involves recombinant technology and does not require a live influenza virus, vaccine can be manufactured within 10 to 12 weeks of identification of a pandemic strain, approximately half the time required to manufacture egg-based vaccines. This new manufacturing approach permits rapid commissioning at a fraction of the cost of traditional, egg-based manufacturing facilities. VLP-based vaccines may represent an effective and affordable component of a pandemic solution for countries that do not currently have in-border pandemic vaccine production.

[Mike Philbin]

NOVAVAX
novel vaccines for novel viruses?

that's what the EU's calling this swinebirdhuman flu now, a novel virus.

[Sane]

NOVAVAX
novel vaccines for novel viruses?

that's what the EU's calling this swinebirdhuman flu now, a novel virus.

where did you see that, picure, screenshot, kink, etc.

[Pilikia]

"Preclinical" - so this means they can skip the standard testing trials and go directly to the infected masses. Why wait? There are stock shares to support.

[Sane]

Novavax begins human clinical testing of novel pandemic flu vaccine
http://www.news-medical.net/?id=28272
Published: Wednesday, 1-Aug-2007

Drug Trials

Novavax has announced that it has begun vaccinating healthy volunteers in the first human clinical trial of its virus-like particle ("VLP") based pandemic influenza vaccine.

The Phase I/IIa randomized, placebo-controlled clinical trial will evaluate the safety and immunogenicity of different doses of the H5N1 clade 2 VLP influenza vaccine in up to 230 healthy adults. The goals of the study are to demonstrate safety and to select a dose for evaluation in a Phase IIb immunogenicity study. The first subject was enrolled at Healthcare Discoveries in San Antonio, Texas, one of two U.S. clinical sites participating in the study.

Novavax is developing vaccines to treat influenza and other viral diseases based upon VLP technology. The technology creates vaccine particles in cell culture that mimic the three-dimensional structure of the virus, but do not contain genetic material and cannot replicate. The flu VLPs are designed to have a favorable safety profile and potentially be more immunogenic than current pandemic vaccines, without the use of an adjuvant. Recent preclinical studies have supported this hypothesis by showing that Novavax's influenza VLPs induced a robust immune response.

"The start of this clinical study represents a major milestone in the company's strategy to develop novel and improved vaccines for the 21st Century," stated Penny Heaton, M.D., Novavax Vice President and Chief Medical Officer. "The pandemic influenza vaccine is the first application of our proprietary VLP technology against a looming public health problem." 

"To create a novel vaccine clinical candidate within two years of focusing Novavax into a vaccine company is testament to our employees' diligence and belief in our mission. The value of this clinical trial is far reaching since it will help us better understand the broad potential of the Company's novel VLP vaccine technology platform with key human data," stated Rahul Singhvi, Chief Executive Officer.

[Pilikia]

I heard about the 'novel' flu name on CNN (Jeannie Moos) last night.

[Sane]

I heard about the 'novel' flu name on CNN (Jeannie Moos) last night.

About what time and time zone?

[Pilikia]

Hmmm... EST, but what time - must have been in the 7pm range when I got home from work. I was watching the last minutes of Wolf BLitzer ...

[Sane]

Novavax reports positive preclinical results on its novel vaccine for pandemic influenza
Main Category: Respiratory / Asthma
Also Included In: Flu / Cold / SARS
Article Date:  9:00 PDT - 26 Aug 2005

Novavax, Inc today reported preclinical results on the Company's novel Virus-Like Particle (VLP) influenza vaccine. Novavax's biological group led by Dr. Gale Smith, together with Dr. Tumpey and Dr. Bu from the Centers for Disease Control and Prevention, published the detailed results in the August 15 online edition of the journal Vaccine. The study demonstrates that a H9N2 influenza virus (avian flu) vaccine produced with the Company's proprietary VLP technology is effective in protecting animals when challenged with live H9N2 influenza virus.

"Our VLP technology, based on a scalable process with short production lead times, offers an attractive alternative to the existing egg-dependent and the newer cell-based methods for the manufacture of influenza vaccine and other urgently needed vaccines. These advantages address the challenge of producing large quantities of a pandemic flu vaccine within a short timeframe," said Rahul Singhvi, President and CEO of Novavax. "This publication demonstrates the value of Novavax's VLP vaccine pipeline. Our plan is to advance our VLP technology into clinical trials with both pandemic and seasonal versions of influenza VLP vaccines."

The work, published in the peer-reviewed journal Vaccine, was completed in collaboration with the Center for Disease Control and Prevention. It involved VLP vaccines constructed from proteins (HA, NA, and M1) produced from genes cloned from avian H9N2 influenza virus by Novavax at the CDC. The animals, vaccinated with a low dose of VLP without the addition of an adjuvant, developed antibodies after the first subcutaneous immunization. Immune responses increased after booster inoculation, and were shown to be protective when challenged with the H9N2 influenza virus. To view the article visit the Company's website at http://www.novavax.com.

"VLP vaccines depend on human immune mechanisms which are highly effective at recognizing and mounting a response against particles the general size and structure of viruses. The nanometer size and structural similarity of VLP vaccines to a live virus enable efficient interaction at a cellular level. VLP vaccines safely imitate whole virus vaccines and can never cause infection since they do not contain genetic material from a virus. Our VLP vaccines for flu, HIV/AIDS and other diseases are proving to be effective at stimulating immunity even at low doses and without the addition of chemical adjuvants," said Dr. Gale Smith, Vice President Vaccine Development of Novavax.

The study was supported in part by a grant from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH) to develop avian flu vaccines using VLP technology. The Company expects to continue working on its Avian Flu vaccine program and produce vaccine for testing in human clinical trials. Significant progress is also being made with VLP vaccines for AIDS and SARS with the support of grants from the NIH.

About Avian Flu Viruses

Avian flu viruses are gaining worldwide attention as a strain of the virus has spread in migratory birds throughout most of Asia and Russia causing millions of birds to die from infection. Concern is growing of a potential pandemic if the virus was to become easily transmitted from human to human. There is no means to predict which specific strain of avian flu will prove capable of human to human transmission. For this reason new vaccine production methods that are rapid, not dependent on limited supplies of fertilized eggs, and ideally effective at standard doses are needed to assist health authorities in meeting the challenge of the demand for a pandemic vaccine.

About Virus-Like Particle (VLP) Technology

Novavax's VLP technology uses recombinant protein technology to imitate the important three dimensional structures of the influenza virus to provide protection without the risk of infection or disease and without the addition of chemical adjuvants. Novavax's proprietary production technology lowers the cost and eliminates the labor intensive nature of the traditional egg based process by using insect cells. The VLP technology produces safe and effective vaccine products through an aseptic process that reduces contamination risk and produces high, cost-effective yields. A key advantage of the technology is the ability to rapidly respond to emerging threats or new strains. A VLP vaccine can be engineered within a few weeks of the discovery of a new virus, after the publication of its DNA sequence data by the government. VLP vaccines can be manufactured within a three day production process in an insect cell system widely used in the biotechnology industry.

About Novavax, Inc.

Novavax, Inc. is a specialty biopharmaceutical company focused on the research, development and commercialization of products utilizing its proprietary drug delivery and biological technologies for large and growing markets. Novavax currently distributes a line of prescription pharmaceutical products, including its topical emulsion for estrogen therapy ESTRASORB, and prenatal vitamins.

[Sane]

[Note: There s a pdf called "About Pandemic Flu" here: www.novavax.com/download/File/pandemic_for_web.pdf  If anyone could copy the text and post it, that would be super cool.thanks]

NOVAVAX
http://www.novavax.com/

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based potent, recombinant vaccines utilizing a new and efficient manufacturing approach.

Our world-class scientific team is using virus-like particle (VLP) technology to tackle influenza viruses – including avian strains that have the potential to cause a pandemic outbreak. Our team has created vaccines designed to protect against various circulating strains of avian influenza as well as seasonal flu, Respiratory Syncytial Virus (RSV) and Varicella Zoster Virus (VZV). We have validated our approach in animals and are now in clinical testing with our pandemic and seasonal influenza vaccine.

Our vision is a holistic approach to controlling the spread of disease. Using a unique portable manufacturing system that allows for rapid mass production, our long-term goal is to be able to rapidly deliver a customized vaccine in the midst of a pandemic.

Novavax plans to apply its particle-based vaccine approach to other viral diseases beyond influenza.

~~~~~~~~~~~~~~~~~~~~~~~~~~~

Board of Directors

John Lambert, Chairman
Former President of Chiron Vaccines, current director of J.G. Solutions Ltd.

Gary C. Evans, Lead Director
Chairman and Chief Executive Officer and founder of Green Hunter Energy, Inc., Owner and co-founder, Wind Hunter, LLC, Retired Chairman, President and Chief Executive, Magnum Hunter Resources, Inc.

John O. Marsh, Jr.
Distinguished Professor of Law, George Mason University, Former Secretary of the Army and U.S. Congressional Representative

Michael A. McManus, Jr.
President, Chief Executive and Director, Misonix, Inc.

Thomas P. Monath, M.D.
Partner, Kleiner Perkins Caufield Byers

Rahul Singhvi, Sc.D.
President and Chief Executive, Novavax, Inc.

James B. Tananbaum, M.D.
Managing Director, Prospect Venture Partners

The chart below describes the structure of Novavax's Board of Directors and its committees.    Audit Committee   Compensation Committee   Corporate Governance Committee
Gary C. Evans    X       Chairman
John O. Marsh    X   Chairman   X
Michael A. McManus   Chairman       X
Thomas P. Monath       X   X
Rahul Singhvi           
James B. Tananbaum       X   X


John Lambert, Chairman
Chairman of the Board of Directors of Novavax since March 2007. President, Chiron Vaccines, a biopharmaceutical company, from 2001 to 2005.  President, Aventis Pasteur MSD, a vaccine joint venture established between Aventis (now Sanofi) and Merck Vaccines, 1998 to 2000.  Currently the Vice President of the Conseil d’Administration of Farmaprojects S.A. (Spain), Non-Executive Chairman of Cambridge Biostability Ltd. (U.K.) and Non-Executive director of Acambis plc (U.K.).

↑ Back to Top

Gary C. Evans, Lead Director
Gary C. Evans is the Chairman and Chief Executive Officer and founder of GreenHunter Energy, Inc., an alternative energy company involved in wind, biofuels and biomass power production listed on the American Stock Exchange.    Mr. Evans is also a principal  in Global Hunter Holdings, L.P., the parent of Global Hunter Securities, LLC., entities active in both direct capital investments and investment banking activities for numerous high growth Chinese based enterprises.

During the prior twenty years until April 2005, Mr. Evans served as Chairman, President and Chief Executive Officer of Magnum Hunter Resources, inc. (a New York Stock Exchange listed company) and Chairman and Chief Executive Officer of all the Magnum Hunter subsidiaries since their formation or acquisition dating back to 1985.       Mr. Evans founded the predecessor company, Hunter Resources, Inc., that was merged into and formed Magnum Hunter Resources Inc., until its merger with Cimarex Energy, Inc. (NYSDE: XEC) during 2005.

Mr. Evans currently serves as the Lead Director of Novavax, Inc., a NASDAQ listed pharmaceutical company.  Mr. Evans serves as an Individual Trustee of TEL Offshore Trust, a NASDAQ listed oil and gas trust.  Mr. Evans was recognized by Ernst & Young as the Southwest Area 2004 Entrepreneur of the Year for the Energy Sector and was recently inducted into the World Hall of Fame for Ernst & Young Entrepreneurs.

↑ Back to Top

John O. Marsh, Jr.
Co-Chair of Independent Review Group for Walter Reed Hospital and Bethesda Navy Medical Center since 2007. Visiting Professor, George Mason University Law School, since 2001. Visiting Professor, Virginia Military Institute, 1998. Interim Chief Executive Officer of Novavax from July 1996 to March 1997 and Chairman of the Board of Directors from July 1996 to February 1997. Secretary of the Army from 1981 to 1989. Counselor with Cabinet rank to the President of the United States from 1974 to 1977. Assistant for National Security Affairs to Vice President of the United States, 1974. Assistant Secretary of Defense from 1973 to 1974. U.S. Representative in Congress from 1963 to 1971.

↑ Back to Top

Michael A. McManus, Jr.
President, Chief Executive Officer and Director of Misonix, Inc., a medical, scientific and industrial provider of ultrasonic and air pollution systems, since 1998. President and Chief Executive Officer of N.Y. Bancorp from 1990 to 1998. Assistant to the President of the United States from 1982 to 1985. Currently a director of LQ Corporation, Inc., American Home Mortgage Holdings, Inc. and A. Schulman Inc.

↑ Back to Top

Thomas P. Monath, M.D.
Partner, Kleiner Perkins Caufield & Byers. Chief Scientific Officer and Executive Director, Acambis Inc., 2003 to 2006. Vice President, Research & Medical Affairs, Acambis Inc. 1992 to 2003. Director, Sanaria Inc. 2005 to 2006. Medical Advisory Board, Symphogen A/S 2005 to 2006. Scientific Advisory Board, Transform Pharmaceuticals, 2005 to present, IAVI 2007 to present. Consultant to Acambis Inc., specifically for smallpox vaccine 2006 to 2007. Currently a director of two private life science companies — Juvaris BioTherapeutics and Xcellerex, Inc.

↑ Back to Top

Rahul Singhvi, Sc.D., M.B.A.
Dr. Singhvi is a recognized vaccine specialist, manufacturing expert and business leader in the pharmaceutical industry. Since assuming his current position, Dr. Singhvi has restructured Novavax to focus on product innovation and development, in particular influenza vaccine development using the company’s novel virus-like particle and Novasome® paucilamellar vesicle technologies.

Before joining Novavax, Dr. Singhvi headed vaccine manufacturing operations at Merck & Co., where production increased by 25 percent at the two plants he oversaw.

Dr. Singhvi received his M.S. and Sc.D. degrees in Chemical Engineering from the Massachusetts Institute of Technology. He also holds an M.B.A. from the Wharton School.   

↑ Back to Top

James B. Tananbaum, M.D.
Managing Director of Prospect Venture Partners II and III, LLC, a dedicated life science venture fund group which he co-founded in 2000. Chief Executive Officer of Theravance, Inc., a biopharmaceutical company, from 1997 to 2000. Partner, Sierra Ventures, a venture capital firm, from 1993 to 1997. Senior Product Manager of Merck & Company, Inc. from 1991 to 1993. Currently a director of Jazz Pharmaceuticals, a private biopharmaceutical company and the following publicly traded biopharmaceutical companies: Critical Therapeutics, Inc., Vanda Pharmaceuticals, Inc. and Infinity Pharmaceuticals, Inc.

~~~~~~~~~~~~~~~~~~~~~~~~~

Management Team

President and Chief Executive Officer
Rahul Singhvi, Sc.D., M.B.A.

Senior Vice President, Commercial Operations
Raymond J. Hage, Jr., M.B.A.

Vice President, Development and Chief Medical Officer
Penny M. Heaton, M.D.

Vice President, Vaccine Development
Gale Smith, Ph.D.

Vice President, Technical and Quality Operations
James Robinson

Vice President, Strategy
Thomas S. Johnston, B.S., M.B.A

Biographies

President and Chief Executive Officer
Rahul Singhvi, Sc.D., M.B.A.

Dr. Singhvi is a recognized vaccine specialist, manufacturing expert and business leader in the pharmaceutical industry. Since assuming his current position, Dr. Singhvi has restructured Novavax to focus on product innovation and development, in particular influenza vaccine development using the company’s novel virus-like particle and Novasome® paucilamellar vesicle technologies.

Before joining Novavax, Dr. Singhvi headed vaccine manufacturing operations at Merck & Co., where production increased by 25 percent at the two plants he oversaw.

Dr. Singhvi received his M.S. and Sc.D. degrees in Chemical Engineering from the Massachusetts Institute of Technology. He also holds an M.B.A. from the Wharton School.     

↑ Back to Top

Senior Vice President of Commercial Operations
Raymond J. Hage, Jr., M.B.A.

Mr. Hage is an experienced pharmaceutical marketer who has overseen the marketing of several major drugs over the past 15 years. Mr. Hage oversees business development and marketing strategy. Prior to joining Novavax, Mr. Hage held marketing positions at Eli Lilly & Co. and Cephalon, Inc.

Mr. Hage received a B.S. in Business and Economics from the University of Kentucky and an M.B.A. from Ohio State University.

↑ Back to Top

Vice President and Chief Medical Officer
Penny M. Heaton, M.D.

Dr. Heaton is responsible for all medical and regulatory affairs at Novavax including the preclinical and clinical development programs for the company’s pandemic and seasonal influenza vaccines. She joined Novavax after a seven-year career at Merck & Co.’s Research Laboratories, where she served as senior director of vaccines clinical research. While at Merck, she oversaw all aspects of the global development of RotaTeq®, the company’s vaccine against rotavirus, which has been filed for licensure in more than 100 countries and is currently recommended for all infants in the United States.

A graduate of the University of the Louisville School of Medicine in Kentucky, Dr. Heaton began her career at the U.S. Centers for Disease Control and Prevention Foodborne and Diarrheal Diseases Branch where she served as a medical officer in the Epidemic Intelligence Service. She was responsible for investigating disease outbreaks as well as conducting surveillance and epidemiologic studies. Dr. Heaton is a member of the Pediatric Infectious Diseases Society and a fellow of the American Academy of Pediatrics.

↑ Back to Top

Vice President of Vaccine Development
Gale Smith, Ph.D.

Dr. Smith is a leader in vaccine technology and holds numerous patents for the baculovirus-insect cell expression system, influenza vaccines and adjuvants. At Novavax, Dr. Smith has developed the first known commercial, scalable process for the manufacture of virus-like particle vaccines for influenza. He also has collaborated with the U.S. Centers for Disease Control and Prevention in testing a virus-like particle vaccine to protect animals against the H9N2 influenza. Prior to joining Novavax, Dr. Smith led a team at Protein Sciences Corp. that developed the first experimental vaccine for HIV approved by the U.S. Food and Drug Administration for testing in the United States. Dr. Smith also collaborated with the National Institute of Allergy and Infectious Diseases and the National Institute of Health to produce the first experimental vaccine tested in man against the H5N1 avian influenza.

Dr. Smith did graduate work at the Baylor College of Medicine and has a Ph.D. in Microbiology from Texas A&M University.

↑ Back to Top

Vice President of Technical and Quality Operations
James Robinson

Mr. Robinson is responsible for process and analytical development, clinical manufacturing, QC and QA for Novavax. His team has developed a process for manufacturing recombinant virus-like particle influenza vaccine using insect cells that will use 100% single-use systems. Mr. Robinson joined Novavax after more than 20 years at sanofi pasteur, a division of the sanofi aventis group, where he most recently served as Vice President of Industrial Operations.  In that capacity, Mr. Robinson was responsible for all aspects of sanofi's US sterile manufacturing operations including quality control, production planning, engineering, warehousing, outsourcing, and strategic planning. 

Mr. Robinson began his career at G.D. Searle & Co. as a pilot plant manager in the company's NutraSweet Division.  In 1986 he joined sanofi as a vaccine production supervisor.  He held various positions in manufacturing, engineering, and product development before being named vice president in 1998. He is a graduate of Lehigh University, where he earned Bachelor's and Master's degrees in chemical engineering.

 

↑ Back to Top

Vice President of Strategy
Thomas S. Johnston,  B.S., M.B.A.

Mr. Johnston is responsible for managing Novavax’s corporate strategic planning process, evaluating potential strategic opportunities and managing select initiatives, including the GE Healthcare collaboration, for development through to proof of concept.  Prior to joining Novavax, Mr. Johnston served as an executive level strategic consultant in a number of industries including biotech, financial services, and electronic security, with clients such as Novavax, RBC Bank and the U.S. Department of Homeland Security. Earlier in his career, Mr. Johnston held varying senior-level positions with a number of organizations such as Comcast, Microsoft, and Schlumberger.  In each role he was able to apply a unique combination of corporate strategy, marketing and finance skills with product level and often technical skills.  Tom holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University.

~~~~~~~~~~~~~~~~~~~~~~~~~

Events & Presentations

World Vaccine Congress 2009
Washington, D.C.
April 20, 2009  3:20 pm
Panel Session Speaker: Dr. Rahul Singhvi
April 23, 2009  11:20 am
Presentation:  Ray Hage
Commercialisation of virus-like particle vaccines using disposable manufacturing systems
April 23, 2009  12:10 pm
Panel Session Speaker: Ray Hage
No webcast for these sessions

Novavax, Inc., Annual Shareholder Meeting
9920 Belward Campus Drive
Rockville, MD
May 13, 2009  10:00 am

2009 BIO International Convention
Atlanta, GA
May 20, 2009 4:00 pm
Panel Presentation:
"Blockbusters Aren't Dead: They're Just Called Vaccines"
Panel Speaker: Thomas S. Johnston
Presentation will be available here

Phacilitate Vaccine Forum Barcelona 2009
Barcelona, Spain
June 22, 2009   9:05 am (CST)
Panel Session Speaker: Dr. Rahul Singhvi
June 23, 2009  9:05 am (CST)
Panel Session Speaker: Dr. Rahul Singhvi
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

R&D Programs
Influenza Vaccines

Novavax is targeting its research efforts initially on various strains of viral influenza. These include H5N1 pandemic influenza, often referred to as “bird flu,” and seasonal influenza, the flu strain that circulates each year. Novavax’s pre-clinical data show the company’s VLP vaccines provide broad protection against a variety of influenza viral strains. Human clinical studies using Novavax' s pandemic VLP vaccine began mid-2007.

Novavax’s collaborators on the influenza vaccines programs include the University of Pittsburgh and the Southern Research Institute, which is one of a handful of U.S. research facilities approved to handle live H5N1 avian influenza virus.

Flu Facts
Varicella Zoster Virus Vaccine

VZV is responsible for over 1 million cases of herpes zoster (shingles) in the US each year.
   Primary complication is post-herpetic neuralgia (PHN), which occurs in ~65% of affected patients.   


 

Large market with only one vaccine supplies:
Government has issued a universal recommendation for all US citizens >60 years of age to be vaccinated against VZV

Current vaccine provides ~50% efficacy against shingles and ~39% efficacy against PHN.

Potential advantages of Novavax’s VZV vaccine:
Broad immune response
Potential safety advantages because of lack of replication
Manufacturing efficiencies: live VZV not needed for process
Vaccine is currently in discovery/preclinical development
HIV

Novavax has created a VLP-based vaccine to protect against human immunodeficiency virus (HIV), the virus that causes AIDS, with funding support from the National Institutes of Health. Scientific collaborators at Harvard Medical School, Emory University and the University of Alabama - Birmingham, have conducted pre-clinical testing using the vaccine. Further evaluation is under way.
Other Vaccine Opportunities

Novavax’s VLP approach has many potential applications and could be used to address a number of other common infectious diseases.

For more information about clinical trials with Novavax influenza vaccines, click here.

~~~~~~~~~~~~~~~~~~~~~~~~~

Flu Facts

Seasonal Influenza is a viral infection that attacks the respiratory tract including the nose, throat and occasionally the lungs. The infection, which usually lasts about a week and is highly contagious, is characterized by fever, headache, muscle aches, cough and sore throat.

Each year epidemic (seasonal) influenza infects between three million and five million people worldwide and results in 250,000 to 500,000 deaths. Most of these deaths are associated with complications from pneumonia. The elderly are the most vulnerable.
Influenza Virus Particle

This flu particle has a spiny coat made of proteins that encapsulate its segmented RNA, the genetic material

Avian influenza is a virus that normally affects only birds. However, sometimes influenza viruses that infect animals may adapt to infect people. In 1997, the first case of H5N1 avian influenza to infect humans was documented in Hong Kong. Since then, the H5N1 virus has spread across Asia, has mutated and has infected hundreds of people, killing approximately half of those infected. Avian influenza in humans is characterized by an unusually high mortality rate, including otherwise healthy people of all ages, and is believed to have pandemic potential.

The H5N1 avian influenza virus is rapidly evolving into antigenically distinct clades, or families. H5N1 clade 1 flu viruses were identified in Vietnam in 2003; by 2005 a second clade was identified in Indonesia. Novavax scientists have succeeded in making a vaccine candidate designed to protect against the H5N1 clade 2 influenza virus.Recent Avian Influenza Strains That Have Infected Humans
H5N1   Identified in 1997 in Hong Kong, since detected in Cambodia, China, Indonesia, Thailand and Vietnam
H7N7   Identified in 2003 in the Netherlands
H9N2   Identified in 1999 in Hong Kong
H7N3   Identified in 2004 in Canada


Influenza pandemics are rare but typically recur every 10 to 50 years. A pandemic occurs when:
A novel subtype of influenza infects humans who are immunologically naïve to the virus
The virus causes severe mortality in humans; and
The virus spreads efficiently from human to human Influenza Pandemics of the 20th Century
1918   The Spanish flu caused approximately 40 million deaths
1957   The Asian flu caused approximately 2 million deaths
1968   The Hong Kong flu caused approximately 1 million deaths

~~~~~~~~~~~~~~~~~~~~~~~~~~

[Sane]

ATCC Develops and Isolates Novel Avian Flu Monoclonal Antibodies
http://www.pr-inside.com/atcc-develops-and-isolates-novel-avian-r1119084.htm
2009-03-16 18:02:02 -


ATCC® (American Type Culture Collection) researchers have developed a panel of novel monoclonal antibodies (mAbs) against avian influenza viruses. These antibodies could lead to a rapid diagnostic test for the infection, ATCC announced today. The organization has filed a patent covering the development of these novel antibodies.

These monoclonal antibodies (mAbs) specifically target the hemagglutinin molecule of three avian influenza A

subtypes. Historically, these target viruses have caused lethal outbreaks in poultry. If they acquire the ability to be transmitted efficiently from human to human, they could potentially cause a worldwide pandemic.

“Given the potential for H5, H7 and H9 avian influenza to jump species and cause a public health crisis, we focused our efforts on developing reagents to detect avian influenza strains which have the potential to cause pandemic disease in humans,” explained Cohava Gelber, PhD/MBA, ATCC Chief Science and Technology Officer.

The antibody-based diagnostic test that is being developed by ATCC is designed to provide information about the virus subtype, a capability that is not currently found in existing rapid influenza diagnostics.
Using a nasal swab, healthcare practitioners could quickly distinguish between a strain of seasonal influenza that is already circulating in the human population and an emerging strain of bird flu, to which humans have no pre-existing immunity.

Although the ATCC research was targeted at a rapid diagnostic test for human infections, it may also be useful for detecting the virus in domestic poultry and wild aquatic birds, the natural reservoirs for influenza viruses.

“Our research represents a major step toward developing a surveillance tool that the public health community can use to protect the population from avian flu and from a possible flu pandemic,” said John Simms, PhD, ATCC Product Development Scientist and antibody project leader.



History

Historical evidence suggests that influenza pandemics have occurred at 10- to 40-year intervals since the 1600s. Most of these pandemics originated in Asia. Three such pandemics have occurred in the 20th century. The most devastating of these was the Spanish Flu pandemic of 1918–1919, which killed an estimated 50 million people across the globe.

Most influenza researchers believe that highly pathogenic strains of H5N1 avian influenza have the capacity to accumulate the genetic changes that would allow the virus to be passed easily among humans. To date, the H5N1 avian flu has not shown the ability to do so, although the latest World Health Organization figures estimate that it has infected 387 people and killed 245 globally, since 2003. In addition, several outbreaks have occurred in Asian poultry markets, and in several poultry flocks in Western Europe.

The H7N7 subtype of avian influenza has also developed highly pathogenic variants and has demonstrated the capacity to infect several species, including birds, pigs and humans. H9N2 influenza strains have only been documented in low pathogenic form, but several cases of human infection have been confirmed. As the H5, H7 and H9 subtypes do not currently circulate in humans, there is no pre-existing immunity to these strains in the general population and no prophylactic vaccines are currently available. The ability of these strains to cross the species barrier greatly increases their pandemic potential.

ATCC has patents pending for the isolated avian flu antibodies as well as for methods of using the antibodies to diagnose infections with avian influenza virus. The ATCC monoclonal antibodies against avian influenza viruses are available for sale and for licensing.

ABOUT ATCC


ATCC is a private, nonprofit biological resource center (BRC) and research organization whose mission focuses on the acquisition, authentication, production, preservation, development and distribution of standard reference microorganisms, cell lines and other materials for research in the life sciences. Founded in 1925, ATCC is the world’s leading biological resource center. Its mission is to acquire, authenticate, preserve, produce, develop and share biological materials for the advancement of scientific knowledge. ATCC provides these core services to government, industry, education, health care, and research laboratories around the world. ATCC Dionne Dyches, 703-365-2879